Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

“We found that treating patients before bariatric surgery with semaglutide, one of the new GLP-1 medications ... the GLP-1s were given months to years after bariatric surgery, perhaps when ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Follow-up periods ranged from 1 month to 4 years after the index date. The use of semaglutide was associated with an increased risk for NAION among patients with diabetes throughout the study ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Glucagon-like peptide 1 receptor agonist therapy over a 12-month period is safe and effective in treating weight regain ...

New study reveals semaglutide ... at one year. Adult patients with a body mass index (BMI) of at least 30 kg/m 2 who completed a follow-up weight measurement at least 12 months after treatment ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...